摘要:
The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.
摘要:
An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.
摘要:
The present invention is directed to a process for preparing hexamethylenebiscyanoguanidine. This compound is used as an intermediate to prepare chlorhexidine. The formation of the hexamethylenebiscyanoguanidine proceeds under base catalysis in an organic solvent. The base used in accordance with the invention is chlorhexidine itself. In addition, this invention enables the preparation of chlorhexidine base in a so-called one-pot process without intermediate isolation of the HMBCG.
摘要:
Anthranilic acids substituted in the 3- and/or 5-position are valuable intermediates for the production of agricultural chemicals. These substituted anthranilic acids can be obtained in good yield without undesirable isomeric byproducts by the oxidative ring-opening of dihydroquinolin-4-ones or quinolin-2,4-diones with t-butyl hydroperoxide in the presence of a base.
摘要:
A process for the preparation of a substituted guanidine by reacting a substituted cyanamide with ammonia or a substituted amine in the presence of a Lewis acid catalyst. Also disclosed is a process for the preparation of a tri-substituted guanidine by reacting a mono-substituted cyanamide with a di-substituted amine.
摘要:
Die Erfindung richtet sich auf ein verbessertes Verfahren zur Herstellung von 1,6-Di(N³-cyano-N¹-guanidino)hexan aus Alkalidicyanamid und einem Hexamethylendiammoniumsalz in alkoholischer Lösung bzw. Suspension. Die Umsetzung wird in Gegenwart einer begrenzten Menge Wasser und einer katalytischen Menge einer Base, bevorzugt einem tertiären Amin, durchgeführt, wobei der pH-Wert des Reaktionsgemisches zu Beginn der Umsetzung 8 bis 10 beträgt. Nach beendeter Umsetzung wird das Reaktionsgemisch in der Wärme, oberhalb 80 °C, mit Wasser versetzt und das grobauskristallisierende Produkt von der flüssigen Phase abgetrennt. Bevorzugt werden Natriumdicyanamid und Hexamethylendiamin-dihydrochlorid - vorzugsweise aus wäßrigem 1,6-Diaminohexan und wäßriger Salzsäure in situ gebildet - in n-Butanol in Gegenwart von 0,1 bis 20 Gew.-% Wasser, bezogen auf das Lösungsmittel incl. Wasser, bei pH 9 -9,5 umgesetzt. Erfindungsgemäß wird 1,6-Di(N³-cyano-N¹-guanidino)hexan in hoher Ausbeute (85 - 96 %) und hoher Reinheit (95 - 97 %) und mit wesentlich erhöhter Raum-Zeit-Ausbeute gewonnen.
摘要:
The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.